Joel Greenblatt’s Maravai LifeSciences MRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$92K Buy
+12,017
New +$83.1K ﹤0.01% 1838
2025
Q1
– Sell
-347,015
Closed -$1.89M – 1627
2024
Q4
$1.89M Sell
347,015
-120,833
-26% -$777K 0.02% 739
2024
Q3
$3.89M Sell
467,848
-9,796
-2% -$84.7K 0.04% 562
2024
Q2
$3.42M Sell
477,644
-65,944
-12% -$569K 0.04% 535
2024
Q1
$4.71M Buy
543,588
+18,675
+4% +$126K 0.07% 380
2023
Q4
$3.44M Buy
524,913
+900
+0.2% +$5.81K 0.06% 420
2023
Q3
$5.24M Buy
524,013
+188,420
+56% +$2.07M 0.11% 239
2023
Q2
$4.17M Sell
335,593
-18,340
-5% -$248K 0.09% 299
2023
Q1
$4.96M Buy
353,933
+122,524
+53% +$1.76M 0.12% 202
2022
Q4
$3.31M Buy
231,409
+120,232
+108% +$1.89M 0.09% 266
2022
Q3
$2.84M Sell
111,177
-20,740
-16% -$520K 0.09% 285
2022
Q2
$3.75M Buy
131,917
+97,787
+287% +$3.1M 0.12% 206
2022
Q1
$1.2M Buy
34,130
+15,621
+84% +$524K 0.04% 509
2021
Q4
$776K Buy
+18,509
New +$750K 0.03% 620
2021
Q2
– Sell
-6,858
Closed -$244K – 1060
2021
Q1
$244K Buy
+6,858
New +$227K 0.01% 893

Other funds holding MRVI

Joel Greenblatt's MRVI Position: Q3 2026 in Review

Joel Greenblatt opened a new position in Maravai LifeSciences (MRVI) in Q3 2026: 12,017 shares worth $92K. The stake represents ﹤0.01% of the portfolio and ranks #1838 among its holdings. This is a return to the name: Joel Greenblatt previously reported a position in MRVI as recently as Q4 2024.

Joel Greenblatt first reported a position in MRVI in Q1 2021 and has held it in 15 quarters since. The position peaked at $5.24M in Q3 2023. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2026.

  • Joel Greenblatt held 12,017 shares of Maravai LifeSciences worth $92K as of Q3 2026.
  • Maravai LifeSciences was a new Joel Greenblatt position in Q3 2026.
  • Maravai LifeSciences made up ﹤0.01% of Joel Greenblatt's portfolio in Q3 2026, its #1838 holding.
  • Joel Greenblatt first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 15 quarters since.
  • Joel Greenblatt's Maravai LifeSciences position peaked at $5.24M in Q3 2023.
  • 202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.